Aeterna Zentaris (NASDAQ:AEZS) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a report published on Sunday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Price Performance

Shares of NASDAQ:AEZS opened at $1.98 on Friday. Aeterna Zentaris has a fifty-two week low of $1.36 and a fifty-two week high of $3.38. The company has a market capitalization of $9.62 million, a price-to-earnings ratio of -0.58 and a beta of 1.57. The firm’s 50 day simple moving average is $1.95 and its 200 day simple moving average is $1.90.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.